Nanoscale celluloses have recently gained an increasing interest in modern medicine. In this study, we investigated the properties of plant derived nanofibrillar cellulose (NFC) as an injectable drug releasing hydrogel in vivo. We demonstrated a reliable and efficient method of technetium-99m-NFC labeling, which enables us to trace the in vivo localization of the hydrogel. The release and distribution of study compounds from the NFC hydrogel after subcutaneous injection in the pelvic region of BALB/c mice were examined with a multimodality imaging device SPECT/CT. The drug release profiles were simulated by 1-compartmental models of Phoenix Ò WinNonlin Ò . The NFC hydrogel remained intact at the injection site during the study. The study compounds are more concentrated at the injection site when administered with the NFC hydrogel compared with saline solutions. In addition, the NFC hydrogel reduced the elimination rate of a large compound, technetium-99m-labeled human serum albumin by 2 folds, but did not alter the release rate of a small compound 123 I-b-CIT (a cocaine analogue). In conclusion, the NFC hydrogels is easily prepared and readily injected, and it has potential use as a matrix for controlled release or local delivery of large compounds. The interactions between NFC and specific therapeutic compounds are possible and should be investigated further.
Introduction
The use of hydrogels as nanostructured scaffolds and particles in tissue engineering and delivery of therapeutic agents is an emerging field in biomedicine (Geckil et al., 2010; Lu et al., 2013) , as many hydrogels have innate structural similarities with physiological matrices (Slaughter et al., 2009 ). However, there is an ongoing research to improve the properties and quality of these applications, such as structural integrity, biocompatibility, and biodegradability. Recently, cellulose and cellulose-based materials have gained an increasing interest in modern medicine, mostly due to their versatility and inherent properties (Charreau et al., 2013) .
Cellulose is the most abundant naturally occurring biopolymer on earth. The discovered structural features and properties have enabled the creation of novel cellulose-based materials and applications, particularly the emerging investigation of nanoscale celluloses (Charreau et al., 2013) . The cellulose nanomaterials, mostly films and hydrogels, have already shown importance in industrial, pharmaceutical, and biomedical research (Klemm et al., 2011) . In the biomedical field, injectable hydrogels have shown some potential (Jain et al., 2013) ; especially considering the challenges of noninvasive delivery of peptide and protein therapeutics, such as monoclonal antibodies and recombinant human proteins (Jain et al., 2013; Kumar et al., 2006; Muller and Keck, 2004) .
Modern medicine involving drug delivery and therapy with implants and hydrogels, the applications must be non-toxic and biocompatible, while still providing the desired properties and functions for successful treatment. Currently, the modern medicine related research on nanostructural cellulose hydrogels has mostly focused on the use of bacterial celluloses (Innala et al., 2013; Muller et al., 2013; Pretzel et al., 2013) . However, plant-derived nanofibrillar cellulose (NFC) prepared from wood pulp is also one of the emerging nanomaterials with properties for potential biomedical applications (Bhattacharya et al., 2012) . High water content of NFC, like with many hydrogels, provides soft tissue like mechanical behavior and similarity, which inherently improves biocompatibility (Jain et al., 2013) . Furthermore the viscoelastic properties of NFC resemble the physiological properties of extracellular matrices (Bhattacharya et al., 2012; Miron-Mendoza et al., 2010) . The NFC aqueous suspensions behave as 1-compartmental hydrogels with pseudoplastic and thixotropic properties (Pääkkö et al., 2007) . Pseudoplasticity induces a shear thinning effect which reduces viscosity with increased shear stress. Shear thinning therefore enables NFC hydrogels to be easily injected (Bhattacharya et al., 2012) as the extruding force of the syringe is enough to change NFC flow properties to lower the viscosity. While in static conditions, NFC retains higher viscosity due to the rearrangement of the fibers, which reverts the shear thinning effect. As an injectable hydrogel, NFC is able to deliver cells or therapeutic agents (e.g. proteins or peptides) into easily accessible target sites, such as under the skin. Additionally NFC hydrogels are biocompatible, non-toxic, and structurally durable (Märtson et al., 1999; Vartiainen et al., 2011) . As a plant derived material, the NFC hydrogels are obtained from a non-animal and non-human source, being thus xeno-free. Additionally, cellulose based materials offer a broad modification capacity (Klemm et al., 2011) , which is advantageous when designing new biomaterials.
Currently, in biomedical and -pharmaceutical research, the hydrogels under investigation for the potential use of controlled release matrices can prove to be problematic in terms of gel activation properties (Hennink and van Nostrum, 2002) , especially with injectable hydrogels. The need for an external source of activation presents additional complications and toxicity as crosslinking agents often used are potentially toxic compounds (Van Tomme et al., 2008) , that need to be extracted from the gels before usage. This could prove to be difficult in the case of parenteral delivery, such as subcutaneous injections. Furthermore, the crosslinkers may react with the imbedded drug compounds within the hydrogel, which may result to unwanted consequences or ineffective treatment. NFC overcomes this obstacle, as there is no need for activation methods such as the use of UV irradiation or chemical crosslinking due to the pseudoplasticity of the material. After administration (e.g. subcutaneous injection), NFC ''gels'' spontaneously, as the fibers rearrange to form a viscous gel; therefore avoiding all the complications with removing the crosslinking agents, potential toxicity or interactions between the crosslinking agents and the drug compounds in use.
The aim of this study was to investigate the properties of plantderived NFC hydrogel as an injectable platform or ''implant'' for drug release, in addition to examine the utility of SPECT/CT imaging to illustrate the behavior of hydrogels in vivo. We investigated the use of NFC hydrogel as a potential device for local delivery and/ or sustained drug release in an in vivo study with the use of BALB/c inbred mice. Furthermore the use of radiolabeled wood pulp NFC hydrogel as a potential biomedical device amongst other biomedical applications has not been demonstrated before. However, the biocompatibility and toxicity of bacterial and plant-derived cellulose materials have been documented both in vitro and in vivo use with of small animals (Märtson et al., 1999; Vartiainen et al., 2011; Alexandrescu et al., 2013; Roman et al., 2010; Kovacs et al., 2010; Pértile et al., 2011; Helenius et al., 2006; Moreira et al., 2009 ). In addition, we demonstrate a reliable and efficient method for NFC radiolabeling for the purpose of molecular imaging with a small animal SPECT/CT.
Materials and methods

99m Tc-NFC labeling
To image NFC in animals by SPECT/CT, NFC was labeled with Tc-NFC according to a previously described procedure for 99m
Tc-labeled carboxymethyl-cellulose (Schade et al., 1991) 
In vivo imaging, drug release and kinetics
Animal studies were approved by the Finnish National Animal Experiment Board and performed in accordance with the Animal Welfare Act (247/1996) and Good Laboratory Practices for Animal Research. The release properties of plant-derived NFC implants were investigated with the use of radiolabeled small compounds. The use of 99m Tc-NFC allows localization of the NFC in animals. Hydrogel implants were injected subcutaneously in the pelvic region, and the mice were observed non-invasively over a 24 h period with the use of a SPECT/CT system. After the 24 h period, the mice were sacrificed by cervical dislocation. A total of 20 female BALB/c inbred mice were obtained from a professional stockbreeder (Harlan Laboratories, Netherlands) and quarantined for two weeks prior to the start of the experiment. The mice were divided into 7 groups, A, B, C, D, E, F (n = 3) and G (n = 2). The mice in groups A and C were injected with a mixture of saline solution and Iodine-123-Sodium Iodine ( Tc-HSA was prepared, and radiochemical purity was tested according to the manufacturer's instructions (Vasculocis Ò , CIS bio international, France). Radiochemical impurities were found below the allowed 5% of the total activity. SPECT/CT imaging was performed with a four-headed small animal scanner (NanoSPECT/CT Ò , Bioscan, USA), outfitted with 1.0 mm multipinhole apertures. All mice were sedated with isoflurane, and SPECT images were acquired 0 h (with 5 or 6 acquisitions at 15 min intervals), 5 h and 24 h post-injection in 16 projections using time per projection of 45, 90 and 180 s, respectively. CT imaging was accomplished with 45 kVp tube voltage in 180 projections. For 3D co-registration and analysis, the SPECT images were reconstructed with HiSPECT NG software (Scivis GmbH, Germany) and fused with CT datasets by using the molecular imaging suite InVivoScope™ (Bioscan Inc., USA). In the analysis, volumes of interests (VOI's) were drawn at the injection site (whole NFC implant), thyroid glands, stomach, left kidney, heart, and around the striatum depending on the study compound, respectively. Counts within each VOI were recorded, corrected for radioactive decay, and normalized to the activity at the time of injection. 99m Tc-HSA release kinetics was described using the built-in 1-compartmental models of Phoenix Ò WinNonlin Ò (Pharsight, Mountain View, USA). The saline preparations were assumed to be 100% available for absorption immediately after injection. The pharmacokinetic (PK) data obtained from the saline injections were observed against the data obtained from the hydrogels. Deconvolution and Loo-Riegelman models were selected to demonstrate 99m Tc-HSA release, or the amount ready to be absorbed, from the injected hydrogel.
Results
3.1.
99m Tc-NFC labeling Tc to carboxymethyl-cellulose (Schade et al., 1991) . To optimize the labeling condition, we investigated the following parameters: the concentration of stannous chloride solution required for the reduction of 99m Tc (Fig. 1a) , the pH of the labeling solution (Fig. 1b) , and the time required for the labeling reaction to occur efficiently (data not shown). Stannous chloride at 5 lg/ml is shown to be the most optimal; however, the labeling procedure was fairly insensitive towards the concentration changes, and no major effect on labeling efficiency was found between the concentrations of 50 and 0.5 lg/ml (Fig. 1a ). For further studies, the optimal 5 lg/ml stannous chloride concentration was selected. In addition, the changes of pH in the labeling solutions were investigated during the radiolabel preparation. It was observed that the tested pH levels did not have any noticeable effect on the labeling efficiency (Fig. 1b) . Throughout the pH range of 4.74-8.05, the labeling efficiency was found well over 95%. The saline solution (pH of 7.2) was selected for animal studies. Furthermore the incubation times before the TLC radiolabel purity confirmation were examined. It was shown that the incubation times less than 30 min were suboptimal (data not shown). Therefore 30 min incubation time was selected for further studies.
The described 99m
Tc-NFC labeling method for the aforementioned parameters was found highly efficient; typically resulting in over 95% binding rate, while less than 5% of the technetium remained unbound (Fig. 2) . Reference samples without stannous chloride showed little binding efficiency. In addition NFC did not show any inherent binding affinity towards Tc. In preparation for the in vivo animal experiment, the radiolabel stability was studied for a period of 24 h in both saline and fetal bovine serum (FBS) samples (Fig. 3 ). Tc-NFC was shown to be stable in FBS during the 24 h period. In contrast, the radioactivity of the labeled NFC in saline at the 24 h time point was reduced to 40.5%. During the first 4 h, the overall radioactivity of 99m Tc-NFC remained at 81.7% and 87.2% for saline and FBS samples, respectively. Therefore it can be expected that the radiolabel will remain stable during the first stages of the SPECT/CT imaging; however some consideration has to be taken into account while examining the 24 h data.
In vivo imaging, drug release and kinetics models
The location of the NFC hydrogel after injection was investigated with a dual-trace SPECT/CT imaging of 123 I-NaI and 99m Tc-NFC. Images confirm the hydrogel position at the injection site in the pelvic region (Fig. 4) . In addition, the NFC hydrogel remained intact during the image acquisition. In between the first set of images and the 5 h images, the mice were awake and moving freely in their habitats. During this time, the hydrogels did not migrate nor disintegrate. Furthermore, the radiolabel showed stability as predicted from the previous radiolabel stability experiment (Fig. 3) , and the pertechnetate remained at the injection site bound to the NFC hydrogel.
123
I-NaI was mostly distributed into the thyroid glands and stomach, in addition to being excreted to urine. 5 h post injection, no trace of 123 I-NaI was found at the injection site. To explore the use of the NFC hydrogel as a drug release matrix, we selected a small drug ( Tc-HSA were investigated after injecting the NFC hydrogels imbedded with the study compounds. The study compound and saline solution mixtures were used as controls (injections without the NFC hydrogel).
The differences between the HSA-NFC hydrogel ''implants'' and saline injections were observed as 99m Tc-HSA expressed a delayed release from the NFC hydrogel and 41% of the injected dose remained within the hydrogel 5 h post injection (Fig. 5a ). Linear release was observed in the beginning of the study, and release rates calculated from the early time points (from first to 5 h) resulted in À0.0233 lg/h and À0.0139 lg/h for saline solution and hydrogel injections, respectively. Release of 99m Tc-HSA was steady during the whole study. In addition, a large distribution of 99m
Tc-HSA was shown in the subcutaneous tissue surrounding the injection site indicating a very poor absorption of 99m Tc-HSA into the circulatory system (Fig. 5b) . Slight activity was detected within the bloodstream, as indicated by the radioactivity in heart and left kidney (Fig. 6) . However, the distinctions between the compound itself and its metabolites cannot be made, as it is well known that 99m
Tc-HSA does not pass the glomerular filtration under normal renal activity. Slow absorption is probably due to the large protein size and low enzymatic activity within the subcutaneous tissue. It was shown that injections given with NFC hydrogel retained 99m Tc-HSA in a smaller area within or around the hydrogel than saline solution injections (Fig. 5b) Tc-HSA to any other organ was detected. No differences between the saline and hydrogel injections were observed in blood pool activity, i.e. heart (Fig. 6a) . However, slight differences were detected in the left kidney of the study animals (Fig. 6b) . The amount accumulated in the left kidney during the study period was low in addition to some of the activity might be due to metabolized 99m Tc-HSA. However the differences indicate a slower absorption from the NFC hydrogel injections. Therefore the limited distribution (smaller surface area) might explain the lower absorption rate from the 99m Tc-HSA/NFC.
To better understand the release profile of 99m Tc-HSA from the NFC hydrogel, we performed pharmacokinetic simulation by using the built-in 1-compartmental models of Phoenix Ò WinNonlin Ò . We used both deconvolution and Loo-Riegelman models to depict the fraction that is ready to be absorbed from the initial injection site, i.e. the hydrogel. Both models show similar profiles, in addition to most of the dose being ready for absorption at the 24 h time point. Both pharmacokinetic models built for 99m Tc-HSA showed an absorbed fraction of $0.43 over 15 min post-injection (Fig. 7) . The release was shown as 1st order kinetics. The computational elimination rate constants were 0.108 h À1 and 0.209 h À1 from the hydrogel and saline solutions, respectively (Supplementary Table 1 ); therefore showing a 2-fold slower rate of elimination of 99m Tc-HSA from the injection site when given with the hydrogel. It should be noted that the absorbed fraction depicted in the pharmacokinetic models does not describe the absorption that was seen in the SPECT/CT images, but rather the distribution within the subcutaneous tissue. The SPECT/CT images show a clear signal for Tc-HSA at 24 h post-injection. In contrast to a larger compound, 99m Tc-HSA that showed a slow release from both NFC hydrogel and saline mixture (Fig. 5) , the small compound 123 I-b-CIT was released rapidly from the NFC injections (Fig. 8) . 5 h post-injection Tc-HSA, as the NFC hydrogel retains the study compound within itself and a smaller area than with the saline injections. Therefore a better indication for smaller compounds with the use of NFC hydrogels might be local delivery rather than delayed delivery which was observed with the larger compound 99m Tc-HSA.
In summary, the release rate and distribution of 99m Tc-HSA indicated a clear difference between the NFC hydrogels and saline solutions. The NFC hydrogel caused a 2-fold slower rate of elimination of 99m Tc-HSA from the injection site. The release was shown to be steady during the 24 h study period. Poor absorption was observed, as 99m Tc-HSA distributed mostly in the subcutaneous tissue surrounding the injection site if given with saline solution. The SPECT/CT images show that both study compounds Tc-HSA are more concentrated at the injection site when administered with the NFC hydrogel compared with saline solutions. 24 h post-injection small amounts of 123 I-NaI dose were found in the thyroid glands for both saline and NFC hydrogel injections.
I-b-CIT was mostly distributed into the striatum. Other distribution into specific organs in the periphery was unclear, and no other organs were selected to investigate within this study. 
Discussion
In this study, the drug release properties of a plant-derived NFC hydrogel, GrowDex Ò , as an injectable biomaterial were evaluated. NFC samples were imbedded with the labeled study compound for SPECT/CT small-animal imaging, in addition to dual-radionuclide tracing to confirm the in vivo localization of the hydrogel. Subcutaneous administration in the pelvic region was selected as the most appropriate and convenient for hydrogel implantation. Injections under the skin can overcome some of the delivery problems related to new biopharmaceutical drugs, such as recombinant human proteins or monoclonal antibodies (Kumar et al., 2006; Muller and Keck, 2004) . Additionally, the study compound 99m Tc-HSA would be exposed to the high proteolytic activity in the gut through oral administration. Furthermore, as the native NFC is not naturally degraded in mammals, the subcutaneous site was selected to enable easier later removal of hydrogel implants. First, we investigated the labeling efficiency of NFC with 99m Tc.
The results indicate that after optimization the labeling method showed a high binding rate with less than 5% remaining unbound; therefore achieving a very high binding efficiency. It is possible that the unbound pertechnetate accumulates in the thyroid glands; however the amount (and therefore the signal) remained negligible when compared to 123 I-NaI, which is generally known to accumulate heavily into the thyroid. Additionally, 99m
Tc was not detected in the thyroid glands in its respective channel in the split images (30 min image in Fig. 4 ). It is not fully known what the final complex is between cellulose and technetium; however we propose the formation of a chelate complex between NFC and the transition metal technetium that is reduced by stannous chloride, which is a generally used radioactive labeling method (the technetium reduction method). The reduced form Tc 4+ will form chelate complexes with NFC in the presence of O atoms in the OH groups as it is known that the native NFC is slightly anionic (Kolakovic et al., 2012; Wang et al., 2011) . Furthermore it has been shown that cellulose is capable of forming chelates with other transition metals (Kennedy et al., 1974) . We propose that the Tc 4+ aligns itself between the cellulose molecule chains where the natural interchain bonds take place. The dual-radionuclide tracing SPECT/CT images showed that the NFC implants had remained in their site of implantation during the whole study. The mice have been awake and moving in between acquisitions, which indicate that the NFC hydrogel implants were resisting movement without deforming and did not migrate within the subcutaneous tissue. This suggests that the 0.83% NFC hydrogel is enough to enable fiber rearrangement to revert the shear thinning effect of the extruding force in the needle after administration, which additionally reduces migration of the material within Tc-HSA showed a slower release profile than the smaller study compounds. In addition, a slower release from the NFC hydrogels in comparison to the saline mixtures was observed. The release profiles for both saline and implant injections were steady. (B) SPECT/ CT images of 99m Tc-HSA release from saline (above) and NFC injections (below). NFC hinders the distribution of 99m Tc-HSA within the subcutaneous tissue. In addition absorption is slow from both injections, probably due to the large size of the protein, and low enzymatic activity within the subcutaneous tissue. (C) In the 5 and 24 h SPECT/ CT images of 99m
Tc-HSA saline (left) and NFC injections (right) 99m Tc-HSA is localized in the NFC implants, and its distribution in the subcutaneous tissue is much lower than in the saline injections. In addition, it was shown that larger amount of 99m Tc-HSA was still present within the hydrogel at 24 h, which indicates a slower rate of release from the NFC hydrogels than from the saline injections.
the subcutaneous tissue. Furthermore, the SPECT/CT images indicated that the NFC hydrogels did not degrade or deform as no pertechnetate was observed outside the site of injection, which is supported by the previous studies on cellulose biodurability (Märtson et al., 1999) , flexibility, and structural integrity (Pääkkö et al., 2008) . As a non-biodegradable material in the mammalian body, NFC could find potential use as a surgical tissue adhesive, space-filling injectable biomaterial for tissue repair, long-term or single-dose local drug delivery, and tissue engineering. However, non-biodegradability is generally not desired. The removal of NFC from easily accessible sites (such as from subcutaneous tissue) through surgical means is fairly simple. In addition, the area could be locally treated with cellulose degrading enzymes to disintegrate the NFC hydrogels yielding mostly glucose as the metabolized product. It has been shown that enzymatic degradation of NFC with cellulase is possible without increasing in vitro cytotoxicity (Lou et al., 2014) . However, patient acceptance towards injections is generally poor. Therefore NFC hydrogels have potential as longterm or single-dose local delivery systems, especially with compounds of poor bioavailability or where non-invasive routes remain a challenge. The release and distribution of 123 I-b-CIT (a cocaine analogue) from NFC hydrogel implants were evaluated.
123
I-b-CIT showed rapid release from the hydrogels, mostly distributing into the striatum and slightly around the hydrogel at the injection site.
123 I-b-CIT showed a slightly slower rate of release when imbedded with the hydrogel as opposed to the injections of saline and drug compound solutions. However, due to the rapid release, we determined that 123 I-b-CIT does not show an apparent binding affinity to nanofibrillar cellulose itself. In addition, no major differences were found in the distribution of 123 I-b-CIT between the NFC/study compound injections and the saline/study compound injections. Therefore it is possible that the release of similar small compounds might not be altered by the NFC matrix. However it seems that the NFC hydrogel retains most of the 123 I-b-CIT around itself and does not distribute as easily into the surrounding subcutaneous tissue than with the saline injections. We found it interesting that without affecting much of the release rate of the study compound, Tc-HSA distributed heavily into the surrounding subcutaneous tissue. The release rate of 99m Tc-HSA was steady during the whole study period; however, slower release was observed with the NFC hydrogel injections than with the saline injections. This suggests that NFC as an injectable drug releasing biomaterial is indeed more suitable for larger compounds, such as macromolecular protein and peptide drugs. Additionally, protein drugs suffer from delivery problems, which need to be overcome for effective treatment (Jain et al., 2013) . As an injectable hydrogel, NFC could solve some of the challenges related to the delivery of biopharmaceuticals.
The pharmacokinetic models that we constructed could be used to further evaluate the release properties of NFC or other biomaterials in conjunction with SPECT/CT imaging. In our study the deconvolution and Loo-Riegelman models described the amount ready to be absorbed, which relates to the release rate of the compound. This could be useful in further analyzing poorly absorbing compounds (such as the HSA in our case), and can be used to complement drug-biomaterial studies when small-animal imaging is in use. This is especially true in situations where poor absorption is the reason for an apparent slow rate of release, which might be an erroneous indication by the SPECT/CT. Therefore, the detected activity at the injection site might not be because of slow rate of release from the biomaterial, but actually due to very poor absorption.
As we proposed earlier, the high biodurability of NFC suggests that as for a non-biodegrading material, it could have a potential use as a long-term drug releasing biomaterial; ideal as an extended release product for chronic diseases. In addition, NFC hydrogels imbedded with therapeutic compounds could find a potential application as a local delivery biomedical device. Topical and subcutaneous conditions could be treated with easily injectable NFC hydrogels that can be later enzymatically removed. The steady and continuous release of drug from the hydrogels could be further improved through formulation processes, in addition, nanofibrillar cellulose has not shown cytotoxic properties in previous studies (Vartiainen et al., 2011; Alexandrescu et al., 2013; Pitkänen et al., 2010) , which supports the idea of NFC as a potential biomaterial. However, it should be noted that studies considering the safety of plant-derived NFC in humans have not been done and especially with possible long-term exposure, this should be investigated thoroughly.
The possible chemical interactions between proteins and NFC should be investigated individually. NFC contains many hydroxyl groups as well as some carboxyl groups which might interact with the drug compounds imbedded within the matrix; therefore making the predictions of release profiles difficult for different compounds. However, considering the current increase of interest in pharmaceutical research towards the possibilities of macromolecular protein and peptide drugs, NFC might offer an additional method for parenteral delivery, as the effective delivery of protein drugs has been one of the main challenges in pharmaceutical sciences (Kumar et al., 2006) . It is likely that the native NFC requires modification to perform more effectively in protein delivery. However cellulose based materials are highly modifiable (Klemm et al., 2011) , with which it is possible to improve the properties of NFC in drug release and retaining.
Furthermore, this study did not focus on physical nor chemical properties of the molecules; however the native NFC is known to have a slight negative surface charge (Kolakovic et al., 2012; Wang et al., 2011) , thus it can be expected to have some repelling forces between the negatively charged 123 I-NaI and 99m
Tc-HSA. Indeed, the results indicated that in the dual-radionuclide imaging study, the release of 123 I-NaI was more rapid from the hydrogels than from the control saline injections. The chemical properties are more important in smaller scale, thus the repulsion forces by the negative charges are greater than the hindrance of the nanofibrous matrix of the hydrogel itself, which relates to molecular size, a physical factor.
99m Tc-HSA also has a negative charge; however the size of the molecule is considerably larger than 123 I-NaI, therefore the physical effect of the NFC matrix in the controlled release is more dominant. Positively charged molecules were not investigated in this study, however considering the effects of the negatively charged molecules ( 123 I-NaI and 99m
Tc-HSA); it is likely that a more noticeable sustained release effect would be observed with positively charged molecules.
In addition, during the study on 99m
Tc-HSA and hydrogel preparations, it is unlikely but possible that a small amount of the free/ unbound pertechnetate from the HSA radiotracer would label the NFC matrix while mixing the 99m Tc-HSA solutions with the biomaterial prior to injection. The labeling for both 99m Tc-HSA and   99m Tc-NFC utilized spontaneous stannous chloride reduction methods; Fig. 8 .
123 I-b-CIT was shown to be more concentrated at the injection site with NFC injections. Saline injections distributed to a wider area inside the subcutaneous tissue.
NFC retains both of the study compounds ( 99m Tc-HSA and 123 I-b-CIT) to a smaller area; however the differences in rate of release/absorption for 123 I-b-CIT were small between the injections. This suggests a possible application for local delivery rather than delayed release for smaller compounds used with NFC hydrogels. therefore we believed the labeling mechanism could be the same. Tc-HSA, the amount of free pertechnetate was observed very low (impurities were found below the allowed 5% indicated by the manufacturer). Therefore, only the free portion of the radiolabel amongst the impurities of the total activity is theoretically able to form bonds with the NFC biomaterial, which would still amount to much less than 5% of the whole activity. This suggests that the 99m Tc-HSA related data obtained in this study is still reliable, as the amount of possible erroneous activity detected from the biomaterial during the image acquisition is considerably lower. Most injectable biomaterials are prepared in solution, while the gelation is triggered by an external signal, for example phototriggering (Zhang et al., 2002) or salt-and pH-sensitive self-assembly (Collier and Messersmith, 2004) . In addition many crosslinking agents are known to be toxic (Speer et al., 1980) . Therefore the removal of the potentially toxic crosslinker is required prior hydrogel usage, which may cause additional complications. For NFC, a triggering mechanism is not required, as it is a readily injectable hydrogel in its natural state due to its pseudoplastic and thixotropic properties. This can prove to be advantageous in the use of biomaterials as injectable hydrogels or implants, as there is no additional toxicity or interactions introduced by external activators. Interactions between therapeutic compounds and NFC would still require further investigation; however with the absence of additional activation, processing or crosslinking agent removal, the process is simplified. Additionally, the results indicate that NFC hydrogels could show potential in the delivery of biopharmaceuticals, where parenteral administration could address the delivery problems of protein and peptide drugs. However it is likely that the native NFC requires further modifications for more effective delivery.
Conclusions
In this study, we have demonstrated a reliable and efficient method of 99m Tc-NFC labeling. Further research conducted on NFC hydrogels with molecular imaging can be readily performed with this methodology. In addition, our proposed method can help in evaluating the rate of drug release with the use of pharmacokinetic models in conjunction with molecular imaging in drug-biomaterial studies. In the field of non-invasive or minimal invasive research, NFC has potential use as surgical adhesive, space-filling biomaterial in addition to tissue engineering and repair. We performed our study in mind of a potential controlled release or local drug delivery hydrogel that could be easily prepared and readily injected. NFC did not disintegrate or migrate during the study despite the activity of the study animals while awake between image acquisitions. Potential local delivery or long-term controlled release treating chronic diseases, especially in easily accessible areas such as the skin, could be possible with injectable hydrogels. Removal of NFC after treatment can be performed by small surgery or potentially disintegrated into glucose by locally administering cellulose metabolizing enzymes. NFC does not require external activators or crosslinking agents; in addition to it being biocompatible and non-toxic. Further studies to improve hydrogel handling or with specific therapeutic compounds should be performed. However, we have shown the potentiality of wood pulp NFC in the biomedical field, which is complementary to the research already done with bacterial cellulose.
